K2 Principal Fund, L.P. Biomarin Pharmaceutical Inc Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
A detailed history of K2 Principal Fund, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 30,000 shares of BMRN stock, worth $1.97 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
30,000Holding current value
$1.97 Million% of portfolio
0.18%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.49 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.27 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.24 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$913 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$689 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.2B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...